Genomic predictors of response to doxorubicin versus docetaxel in breast cancer

ABSTRACT: Low topo2a expression and ER-negative status were predictors of response to doxorubicin, while small tumor size and ER-negative status predicted response to docetaxel. Docetaxel was superior to doxorubicin in triple-negative/basal-like tumors, while no significant differences between these drugs were seen in the remaining intrinsic subtypes Keywords: reference x sample reference x sample

ORGANISM(S): Homo sapiens

SUBMITTER: Perou Charles 

PROVIDER: S-ECPF-GEOD-21997 | biostudies-other |

REPOSITORIES: biostudies-other